Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Are you planning to buy expensive handbags or watches?

Thu, 16th Jul 2020 10:48

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts Joice Alves (joice.alves@thomsonreuters.com) and
Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Stefano Rebaudo
(stefano.rebaudo@thomsonreuters.com) in Milan.

ARE YOU PLANNING TO BUY EXPENSIVE HANDBAGS OR WATCHES? (0827 GMT)

The absence of deep-pocketed tourists has now turned attention to local demand for luxury
goods makers, given the re-opening trends in Europe has been so far so good.

BofA's analysts are upbeat on the sector and believe any commentary around European
re-opening trends would be one of the most important catalyst for the reporting season.

But dire numbers cannot be entirely ignored. Cartier maker Richemont is among the
top fallers in Europe today with shares sliding 5.2% to two-week lows after the company said its
Q1 sales nearly halved because of COVID-19's "unprecedented" disruption.

Richemont's numbers came in a day after Burberry warned it will cut 500 jobs as it
sees slow demand recovery, particularly from deep-pocketed tourists.

BofA, which prefers LVMH and Burberry over Kering and Hugo Boss
, says local demand in Europe is driving the recovery as lockdown measures are lifted.

"Our Luxury Demand Indicator fell 53% in Apr-May, but initial Jun-July data is encouraging.
China and Korea continues to accelerate," BofA says.

It sees European luxury revenue down 57% in Q2.

Europe's top asset manager, Amundi, is also keen on the sector as it sees demand rising in
China. More here: LIVE MARKETS-What's hot and what's not in post-lockdown world

Next week, investors will be watching if Christian Dior and Moncler have
anything to say that will help get a picture of what the recovery will look like.

Here is how shares in some major European brands have bounced back nicely since the March
slump.

(Joice Alves)

*****

OPENING SNAPSHOT: HEINEKEN, A BITTER Q2 AFTERTASTE (0742 GMT)

European stocks opened down and are now falling 0.8% with an unscheduled trading update from
Heineken giving a bitter aftertaste to the beginning of the Q2 earnings season.

The Dutch brewer lost over 5% after announcing first-half net revenue fell 16.4% as the
impact of coronavirus-related lockdowns intensified in the second quarter.

No sign of a dynamic V-shaped recovery here even if the end of the quarter saw some
improvement: "After a low point in April, volume started to gradually recover into June as
lockdowns were lifted around the world and customers restored depleted inventories".
Anyhow, the tone ain't particularly merry with another big name, luxury goods group Richemont
giving no sign of a V-shaped recovery - actually no outlook at all - and reporting
"unprecedented levels of disruption" from the COVID-19 pandemic.

Not that Getinge won't cheer up the mood that much: the Swedish medical equipment maker is
up about 4% but that's on a jump in core profit due to high demand for...ventilators.

Another group in the healthcare space jumped: Germany's Sartorius which raised its forecast
for the year.

Among other big losers, there's Ladbrokes owner GVC down 6.5% after announcing that Kenneth
Alexander will step down as chief executive officer after 13 years at the helm.

(Julien Ponthus)

*****

ON THE RADAR: ANOTHER EARLY BATCH OF Q2 EARNINGS (0636 GMT)

European shares are seen opening in the red as risk appetite took a hit by concerns about
deteriorating U.S.-China relations. Investors also have to digest a slew of earnings reports,
which show the size of lockdowns damage.

France's Alstom reports a 27% slump in Q1 sales while Richemont Q1 sales nearly halve after
COVID-19 disruption. Richemont shares are down 4% in pre-market trading.

On a brighter note, Norway's Telenor Q2 earnings beat estimates and the company said it
expects a single-digit decline in its subscription and traffic revenues this year. Experian
first-quarter revenue falls less than feared.

Germany's Zalando shares are up almost 5% in pre market after the online fashion retailer
raised full year guidance as more people shop online.

Global miner Anglo sticks to most of its 2020 output targets but Q2 hit by COVID-19.

Swedish medical equipment maker Getinge also reported a jump in core profit and
order intake in the second quarter as demand for ventilators and other life support equipment
surged.

More news about COVID-19 treatment and vaccine: Early-stage human trial data on a vaccine
being developed by AstraZeneca and Oxford University will be published on July 20, The
Lancet medical journal said. Novartis's Sandoz division says will not make a profit on
15 generic drugs it is making available to developing countries to treat symptoms of COVID-19,
the Swiss drugmaker said on Thursday.

(Joice Alves)

*****

MORNING CALL: U.S.-CHINA TENSIONS HIT ONE MORE TIME (0540 GMT)

European shares are seen opening in the red as risk appetite weakened by growing concerns
about deteriorating U.S.-China relations.

Worries about a dispute between the world's two largest economies over the control of
advanced technologies and the protection of civil liberties in Hong Kong pushed Asian stocks and
U.S. futures down.

Even news that China's economy rebounded more than hoped in the second quarter from a record
slump was not enough to cheer investors up. A surge in coronavirus cases, which is prompting
some governments to reimpose containment measures, is also not helping sentiment.

After touching a one-month highs yesterday on vaccine hopes, European markets are set to
follow Asia lower. Investors will also have to digest a slew of earnings, which will show the
size of lockdowns damage.

Financial spreadbetters at IG expect London's FTSE to open 20 points lower at 6,273,
Frankfurt's DAX to open 97 points lower at 12,834 and Paris' CAC to open 26 points lower at
5,083.

(Joice Alves)

*****

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.